Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Equity (2021 - 2025)

Historic Return on Equity for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 0.07%.

  • Kiniksa Pharmaceuticals International's Return on Equity rose 2600.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year increase of 2600.0%. This contributed to the annual value of 0.1% for FY2024, which is 500.0% up from last year.
  • Kiniksa Pharmaceuticals International's Return on Equity amounted to 0.07% in Q3 2025, which was up 2600.0% from 0.01% recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Return on Equity ranged from a high of 0.79% in Q2 2023 and a low of 0.83% during Q4 2021
  • For the 5-year period, Kiniksa Pharmaceuticals International's Return on Equity averaged around 0.02%, with its median value being 0.07% (2025).
  • In the last 5 years, Kiniksa Pharmaceuticals International's Return on Equity soared by 15400bps in 2023 and then tumbled by -9800bps in 2024.
  • Kiniksa Pharmaceuticals International's Return on Equity (Quarter) stood at 0.83% in 2021, then skyrocketed by 183bps to 0.69% in 2022, then tumbled by -121bps to 0.14% in 2023, then surged by 31bps to 0.1% in 2024, then soared by 171bps to 0.07% in 2025.
  • Its Return on Equity was 0.07% in Q3 2025, compared to 0.01% in Q2 2025 and 0.04% in Q1 2025.